Search results for "MIB"

showing 10 items of 193 documents

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and …

2009

Abstract Background Effects independent from cholesterol reduction on vascular function are considered to importantly contribute to the beneficial effects of statin therapy in cardiovascular disease. We aimed to evaluate the effect of high versus low dose atorvastatin on endothelial dysfunction in patients with coronary artery disease (CAD) in a setting of comparable cholesterol reduction. Methods and results Fifty-eight patients with CAD were randomly assigned to double-blind treatment for 8 weeks with atorvastatin 80mg per day (A80) or atorvastatin 10mg+ezetimibe 10mg per day (A10E10), respectively. Flow-mediated vasodilation (FMD) of the brachial artery, nitroglycerin-mediated endotheliu…

Malemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundEzetimibeDouble-Blind Methodmedicine.arteryInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLMiddle Agedmedicine.diseaseAtherosclerosisEzetimibeEndocrinologyC-Reactive ProteinCholesterolTreatment OutcomechemistryHeptanoic AcidsHMG-CoA reductaseCardiologybiology.proteinAzetidineslipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Matched-pairs analysis of outcomes with bortezomib, melphalan, and prednisone (VMP) treatment for previously untreated multiple myeloma (MM) using lo…

2015

(95% CI: 58-88%), respectively. A formal interim analysis of the Day 90 CR rate was conducted when 65 patients were evaluable, and at that time the Mel only arm was determined to be superior. The study was, therefore, stopped early by the Institutional DSMB. However, with a longer follow up Bu-Mel ultimately resulted in better PFS. Conclusions: Bu-Mel was associated with a significantly lower day 90 CR rate and a significantly higher rate of grade 3-4 non-hematologic toxicity, compared to Mel. However, after a median follow up of 15.7 months, PFS was significantly longer in the Bu-Mel arm. Figure 1 PFS from Day 90 by Treatment Arm

MelphalanCancer Researchmedicine.medical_specialtyLong term follow upbusiness.industryBortezomibUrologyHematologyInterim analysismedicine.diseasecarbohydrates (lipids)OncologyPrednisoneMedian follow-uphemic and lymphatic diseasesToxicitymedicinebusinessneoplasmsMultiple myelomamedicine.drugClinical Lymphoma Myeloma and Leukemia
researchProduct

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

2009

Abstract 131 Introduction. Autologous stem cell transplantation (ASCT) after cytoreductive induction is considered standard of care for younger patients (pts) with multiple myeloma (MM). The previous standard of induction, the Vincristin-Adriamycin-Dexamethasone (VAD) combination, achieves inferior results compared with induction regimens which combine the proteasome inhibitor Velcade (V = Bortezomib) with Dexamethasone (D)(=VD) and a cytostatic drug such as Doxorubicin (PAD = VD plus Doxorubicin). Velcade-based induction therapy was shown to translate into better myeloma control after high dose melphalan and to lead to prolonged progression-free survival. In order to find a more efficaciou…

Melphalanmedicine.medical_specialtyCyclophosphamidebusiness.industryBortezomibImmunologyCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryRegimenRefractoryPrednisoneInternal medicineMedicinebusinessMultiple myelomamedicine.drugBlood
researchProduct

Extraction, Structural Characterisation, and Immunomodulatory Properties of Edible Amanita hemibapha subspecies javanica (Corner and Bas) Mucilage Po…

2021

This research aimed to extract mucilage polysaccharides (MP) from Amanita hemibapha subspecies javanica (Corner and Bas), and further fractionate them using anion-exchange chromatography, yielding two fractions (MPF1 and MPF2). The crude extract, and fractions mainly consisted of carbohydrates (83.5–93.2%) with minor amounts of proteins (5.40–7.20%), and sulphates (1.40–9.30%). Determination of the monosaccharide composition revealed that glucose was the major unit, followed by galactose, mannose, rhamnose, and arabinose. The average molecular weight (MW) of the crude extract and fractions was in the range 104.0–479.4 × 103 g/mol. Interestingly, the crude extract, and fractions did not caus…

Microbiology (medical)chemistry.chemical_classificationArabinosebiologyQH301-705.5ChemistryRhamnoseMannosePlant ScienceFractionationbiology.organism_classificationPolysaccharideimmunomodulatory propertyfunctional foodchemistry.chemical_compound<i>Amanita hemibapha</i> subspecies <i>javanica</i> (Corner and Bas)mucilage polysaccharideMucilageAmanita hemibaphaGalactosemushroomFood sciencefractionationBiology (General)Ecology Evolution Behavior and SystematicsJournal of Fungi
researchProduct

Sulphation and Hydrolysis Improvements of Bioactivities, and Immuno-Modulatory Properties of Edible Amanita hemibapha Subspecies javanica (Corner and…

2021

In this study, the mucilage polysaccharide (MP) from Amanita hemibapha subspecies javanica was prepared by hot water extraction and ethanol precipitation and then fractionated using anion-exchange chromatography equipped with a DEAE Sepharose fast flow column. The most immune-enhancing polysaccharide fraction 2 (MPF2) was subjected to a structural modification such as hydrolysis or over-sulphation. The sulphate and molecular weight (Mw) of over-sulphated (OS1-3) and hydrolysed (HS1-3) derivatives of MPF2 differed between 9.85% and 14.2% and 32.8 and 88.1 × 103 g/mol, respectively. Further, the immune-enhancing properties of MPF2 and its derivatives were tested on RAW264.7 and NK cells throu…

Microbiology (medical)sulphationQH301-705.5Plant SciencePolysaccharideArticlechemistry.chemical_compoundSulfationAmanita hemibaphamushroomAmanita hemibapha subspecies javanica (Corner and Bas)Biology (General)Protein kinase ACytotoxicityReceptorEcology Evolution Behavior and Systematicsimmunomodulatorychemistry.chemical_classificationbiologybiology.organism_classification<i>Amanita hemibapha</i> subspecies <i>javanica</i> (Corner and Bas)mucilage polysaccharideDEAE-SepharosechemistryPerforinBiochemistryhydrolysisbiology.protein<i>Amanita hemibapha </i>subspecies <i>javanica </i>(Corner and Bas)Journal of Fungi
researchProduct

Sekaiza | Sekeiza | Sekaisa

2022

La ceca de Sekaiza se localizó en el yacimiento de Poyo de Mara, hasta ca. 153 a.C., y posteriormente se desplazó al yacimiento de Belmonte, permaneciendo en ese lugar hasta mediados del siglo I a.C., quizás fue destruida durante las Guerras Sertorianas (Burillo y Ostalé 1984: 305-309; Gomis 2001: 33; Burillo 2006: 203-240; Asensio 2001: 89). Se ha discutido la posibilidad de que esta ceca y Bilbilis, dada su proximidad, emitieran moneda de manera simultánea (Burillo, Ostalé 1984), aunque Villaronga (1988) propone una jerarquización de sus emisiones que las haría compatibles. Es una de las cecas celtibéricas con mayor volumen de producción y cantidad de hallazgos. La producción monetaria ha…

MonedaMIB ancient coins CalatayudSeques (Numismàtica)Tresors monetaris (Numismàtica)
researchProduct

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patien…

2015

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg Q2W (also 1-mL volume) in patients not achieving their LDL-C target. Primary endpoi…

Monoclonal antibodymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaInjections SubcutaneousHypercholesterolemiaUrology030204 cardiovascular system & hematologyPharmacologyAntibodies Monoclonal Humanizedlaw.inventionPCSK9Rosuvastatin03 medical and health sciences0302 clinical medicineDouble-Blind MethodEzetimibeRandomized controlled triallawmedicineClinical endpointHumansLow-density lipoprotein cholesterolRosuvastatinIn patient030212 general & internal medicineRosuvastatin CalciumAlirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin; Cardiology and Cardiovascular MedicineRetrospective StudiesAlirocumabDose-Response Relationship Drugbusiness.industryAnticholesteremic AgentsPCSK9Antibodies Monoclonalnutritional and metabolic diseasesCholesterol LDLEzetimibeRosuvastatin CalciumTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineFollow-Up StudiesAlirocumabmedicine.drugAtherosclerosis
researchProduct

Dynamics of natural hemiboreal woodland in the Moricsala Reserve, Latvia: the studies of K. R. Kupffer revisited

2010

Abstract Karl Reinhold Kupffer (1872–1935), an outstanding botanist and plant ecologist, took the initiative that led to the establishment of the first nature reserve in Latvia, on Moricsala Island in 1912. The reserve provided an excellent reference area for natural hemiboreal woodland for future generations. There have been very few studies on the dynamics of natural broadleaved forest in Europe, probably owing to lack of primeval forests of this type. However, Kupffer produced a map of forest types in the reserve with accurate descriptions of the vegetation by layers, and his descriptions include interpretations of forest dynamics processes. This information, together with the present ag…

Nature reservegeographygeography.geographical_feature_categorybiologyForest dynamicsHemiborealEcologyDiameter at breast heightForestryForestryWoodlandVegetationbiology.organism_classificationOld-growth forestQuercus roburScandinavian Journal of Forest Research
researchProduct

DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND …

2017

8036 Background: Daratumumab (D), a human, CD38-targeting mAb, is well tolerated and induces deep and durable responses in patients (pts) with RRMM. We provide an update of CASTOR (NCT02136134), a multicenter, phase 3, randomized study of DVd vs Vd in RRMM. Methods: All pts received ≥1 prior line of therapy (LOT) and were administered 8 cycles (Q3W) of Vd (1.3 mg/m2 SC bortezomib on days 1, 4, 8, and 11; 20 mg PO/IV dexamethasone on days 1-2, 4-5, 8-9, and 11-12) ± D (16 mg/kg IV once weekly in Cycles 1-3, every 3 weeks for Cycles 4-8, then every 4 weeks until progression). Bortezomib-refractory pts were ineligible. Minimal residual disease (MRD) was assessed upon suspected CR and at 6 and…

Oncology0301 basic medicinemedicine.medical_specialtyCancer Research02 engineering and technologyPharmacology03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineInternal medicine0202 electrical engineering electronic engineering information engineeringmedicineIn patientDexamethasoneBortezomibbusiness.industryDaratumumabRefractory Multiple MyelomaHematologyGeneral Medicinestomatognathic diseases030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessmedicine.drugHematological Oncology
researchProduct

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

2021

PETHEMA/GEM Cooperative Group.

OncologyAdultBoron CompoundsMalemedicine.medical_specialtyNeoplasm ResidualPhysics::Instrumentation and DetectorsClinical Trials and ObservationsImmunologyPatient subgroupsGlycineDrug resistanceBiochemistryDexamethasoneBortezomibhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmHumansProgression-free survivalTreatment resistanceLenalidomideComplete responseMultiple myelomaAgedChromosome AberrationsLymphoid Neoplasiabusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseFlow CytometryProgression-Free Survivalbody regionsClinical trialTreatment OutcomeDrug Resistance NeoplasmFemalebusinessMultiple Myeloma
researchProduct